2 results
Approved WMOCompleted
The primary objective is to assess treatment with rovalpituzumab tesirine improves overall survival rate (OS) compared to topotecan in subjects with DLL3high SCLC who have first disease progression during or following front-line platinum based…
Approved WMOCompleted
Primary Objective:* To evaluate the effect of treatment with omecamtiv mecarbil (OM) compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) following 20 weeks of treatment with OM or placeboSecondary…